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Background: The study was designed to evaluate the association of GATA4 gene polymorphism with coronary
artery disease (CAD) and its metabolic risk factors, including dyslipidaemic disorders, obesity, type 2 diabetes and
hypertension, following a preliminary study linking early onset of CAD in heterozygous familial
hypercholesterolaemia to chromosome 8, which harbours the GATA4 gene.
Results: We first sequenced the whole GATA4 gene in 250 individuals to identify variants of interest and then
investigated the association of 12 single-nucleotide polymorphisms (SNPs) with the disease traits using Taqman
chemistry in 4,278 angiographed Saudi individuals. Of the studied SNPs, rs804280 (1.14 (1.03 to 1.27); p = 0.009) was
associated with CAD (2,274 cases vs 2,004 controls), hypercholesterolaemia (1,590 vs 2,487) (1.61 (1.03–2.52); p = 0.037)
and elevated low-density lipoprotein-cholesterol (hLDLC) (575 vs 3,404) (1.87 (1.10–3.15); p = 0.020). Additionally,
rs3729855_T (1.52 (1.09–2.11; p = 0.013)) and rs17153743 (AG + GG) (2.30 (1.30–4.26); p = 0.005) were implicated in
hypertension (3,312 vs 966), following adjustments for confounders. Furthermore, haplotypes CCCGTGCC (χ2 = 4.71;
p = 0.041) and GACCCGTG (χ2 = 3.84; p = 0.050) constructed from the SNPs were associated with CAD and
ACCCACGC (χ2 = 6.58; p = 0.010) with myocardial infarction, while hypercholesterolaemia (χ2 = 3.86; p = 0.050)
and hLDLC (χ2 = 4.94; p = 0.026) shared the AACCCATGT, and AACCCATGTC was associated with hLDLC (χ2 = 4.83;
p = 0.028). A 10-mer GACCCGCGCC (χ2 = 7.59; p = 0.006) was associated with obesity (1,631 vs 2,362), and the GACACACCC
(χ2 = 4.05; p= 0.044) was implicated in type 2 diabetes mellitus 2,378 vs 1,900).
Conclusion: Our study implicates GATA4 in CAD and its metabolic risk traits. The finding also points to the possible
involvement of yet undefined entities related to GATA4 transcription activity or gene regulatory pathways in events leading
to these cardiovascular disorders.
Keywords: GATA4 gene polymorphism, Haplotypes, Coronary artery disease, Dyslipidaemia, High-density
lipoprotein-cholesterol, Hypercholesterolaemia, Hypertriglyceridaemia, Low-density lipoprotein-cholesterolBackground
The GATA binding proteins constitute a family of cell-
restricted zinc-finger transcription factors (TFs), which
recognize the GATA motif present in the promoters of
many genes. This family, comprising six developmental/
cell-type specific transcription factors, GATA1-6, is
critical to the development of diverse tissues [1-4] and
acts in cooperation with more widely expressed factors
to direct lineage-specific gene expression [5-11]. Their* Correspondence: dzimiri@kfshrc.edu.sa
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reproduction in any medium, provided the ortranscriptional activity is modulated through interactions
with nuclear proteins, including the zinc finger proteins of
the Kruppel and FOG/U-shaped families, general co-
activators of the p300 and cAMP-response element-
binding (CREB) protein (CBP), the myocardial-expressed
protein Nkx2.5, and NF-AT3 [12-15]. In particular, in the
cardiac tissue where its expression is more than 20-fold
greater than in other tissues [16], it is a critical regulator
of cardiac angiogenesis and gene expression, and is in-
volved in modulating cardiomyocyte differentiation and
adaptive responses of the adult heart [5,17,18]. Addition-
ally, GATA4 is abundantly expressed in the endocardium
and endothelial cells, pointing to an important regulatory
control in their development and function [11,19]. Thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cardial tissue suggests a pivotal cardiovascular functional
input, which if perturbed, may lead to various cardiac dis-
orders and coronary artery disease (CAD)-related events.
However, while the importance of this gene is now well
appreciated in congenital heart diseases [20-26] and
some other cardiac malformations [27-29], little is
known about its potential role in vascular activity-
related diseases, such as dyslipidaemia and diabetes
mellitus. Dyslipidaemia can be triggered as a result of a
genetic predisposition, secondary causes, or a combin-
ation of both. However, the genetic causes of this dis-
order remain to be identified. In a preliminary study
investigating the genomic linkage to early onset of
CAD in two Saudi families with heterozygous familial
hypercholesterolaemia (HFH), we identified a locus on
chromosome 8, which harbours the GATA4 gene, as a
plausible candidate for CAD, HFH and harbouring of
low high-density lipoprotein levels. This led to the no-
tion that GATA4 presents a potential candidate for
CAD onset, especially in dyslipidaemic conditions.
Given the lack of information on the role of this gene
in the etiology of atherosclerosis, our study sought to
comprehensively investigate the likelihood of GATA4
polymorphism predisposing individuals to acquiring
the cardiovascular metabolic risk traits, particularly
dyslipidaemia, obesity, type 2 diabetes mellitus and
hypertension, as a potential trigger for the disease on-
set related to these disorders. To this effect, we first
sequenced the gene in the two HFH families and an
additional 250 individuals from the Saudi general popula-
tion to identify potentially informative variants, and then
performed a population-based association study for se-
lected variants with CAD and its risk traits in a larger
cohort of angiographed Saudi individuals.Figure 1 Schematic of GATA4 gene sequence on chromosome 8p23.1
(drawn not to scale). Numbers in rectangles represent the exons.Results
Linkage analysis for dyslipidaemia and early onset
coronary artery disease
The initial scanning of the HFH yielded several peaks in
different genomic regions including Chromosome (Chr) 8,
among others, giving a logarithm of the odds (LOD) score
of 1.8 that isolated at least three of the affected siblings
with the early onset of CAD in both families. One of the
potential culprits at this locus is GATA4, which we elected
to pursue further for its role in dyslipidaemia-related onset
of CAD. Subsequent sequencing of the genes in all mem-
bers of the two HFH families and an additional 250 indi-
viduals led to the selection of 12 single-nucleotide
polymorphisms (SNPs), rs2740434_G > A (minor allele
frequency = 0.26), rs17153743_A >G (0.02), rs13264774_C>
T (0.14), rs56298569_G>C (0.44), rs804280 A>C (0.04),
rs3729855 C>T (0.18), rs3729856_A >G (0.45), rs1062219
C>T (0.45), rs12825_C >G (0.09), rs804291_C>T (0.32),
rs11785481 C>T (0.12), rs3203358 C>G (0.20) for further
case-control studies. Selection of the SNPs was based
partly on the prevalence in our general population and
partly on currently available information of their role in the
disease. Furthermore, these SNPs reside in the later portion
of the gene (also encompassing its three prime untranslated
region, 3′-UTR), which encodes the C-terminal of the
protein and harbours gene regulatory motifs, both of which
are thought to be important in the transcriptional activity
of the GATA4 (Figure 1). We were also curious to under-
stand the potential role of changes in the 3′-UTR in the
disease. Figure 2 displays the linkage disequilibrium (LD)
structure of the ten SNPs included in the haplotyping.
GATA4 genotyping and disease
Since GATA4 constitutes an established risk gene for
congenital heart disease, it was necessary to rule out the. Diagram shows relative loci of studied variants and their positions
D’=0.013-0.83; r2=0.002-0.089
Figure 2 Linkage disequilibrium (LD) structure of ten SNPs included in haplotyping. D′, coefficient of linkage disequilibrium; r,
regression coefficient.
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pertaining to disease trait-gene interactions under inves-
tigation. We therefore first tested for associations of the
gene variants with congenital heart disease as an inde-
pendent patient group (n = 113) in our study population,
using a homogenous set of individuals with dilated car-
diomyopathy (n = 272) as controls. The results pointed
to a significant causative association for the rs3729856
A > G (p.S377G) (Odds ratio (95% confidence interval) =
1.76 (1.19–2.61); p = 0.005), the rs3729856_GG (5.09
(2.14–12.06); p < 0.000001), and rs11785481_TT (6.23
(1.93–20.17); p < 0.002) with congenital heart disease.
Interestingly, in the multivariate analyses for congenital
heart disease versus the rest of the studied population
(113 cases vs 3,969 non-disease individuals), only the
rs11785481_T (1.78 (1.06–3.00); p = 0.030) retained its
significant association (Table 1), pointing to a strong
link that could potentially mask the relationships for
the other diseases in our current study setting. Fur-
thermore, multivariate analyses showed an association
of rs804280_C (1.14 (1.03–1.27); p = 0.009) with CAD
(Table 1), while the rs1062219C > T (p = 0.036) lost this
property, following the adjustment for confounders.
Interestingly, the rs804291_TT was associated with
both hypercholesterolaemia (hChol) (1.61 (1.03–2.52)and elevated low-density lipoprotein-cholesterol (hLDLC)
(1.87 (1.10–3.15); p= 0.020). In contrast, the rs3203358_G
was protective against acquiring both CAD (0.88 (0.78–0.99);
p= 0.042) and hChol (0.86 (0.75–0.98); p = 0.026) (Table 1).
Besides, the rs3729855_T (p.N352N) (1.52 (1.09–2.11)
and rs17153743 (AG +GG) (2.30 (1.30–4.26); p = 0.005)
were implicated in hypertension, while the former ap-
peared to be protective against type 2 diabetes mellitus
(0.68 (0.53–0.88); p = 0.003) (Table 2), also following the
Bonferroni corrections for age, sex, and other confounders
(Additional file 1, GATA4 Suppl data).
GATA4 haplotyping and cardiovascular disease traits
Since several SNPs were associated with the different
cardiovascular disease traits, we were interested in test-
ing the likelihood of these relationships being delineable
at the haplotype level. We employed the most frequent
10-mer GACACACCCG (frequency = 0.145) as the
baseline for the analyses. While the 9-mer haplotype,
ACCCGTGCC (χ2 = 3.80; p = 0.051) was weakly asso-
ciated with CAD, its 8-mer derivative CCCGTGCC
(χ2 = 4.71; p = 0.041) was associated with the disease.
This relationship became stronger with the shortening
of these haplotype sequences, culminating in the 4-mer
ACCC (χ2 = 7.17; p = 0.007) displaying the most significant
Table 1 Association of GATA4 gene variants with
coronary artery disease, myocardial infarction congenital
heart disease
Block Haplotype Pooled Cases Control χ2 p value
Hypercholesterolaemia
1–9 AACCCATGT 0.063 0.071 0.060 3.86 0.050
5–10 CATGTC 0.088 0.096 0.082 4.25 0.039
High low-density lipoprotein
1–10 AACCCATGTC 0.062 0.079 0.062 4.83 0.028
GACCCATGCC 0.015 0.024 0.015 4.94 0.026
1–9 AACCCATGT 0.063 0.078 0.062 4.31 0.038
Hypertriglyceridaemia
2–7 ACACAT 0.083 0.072 0.088 4.79 0.029
2–6 ACCTA 0.013 0.018 0.011 4.65 0.031
3–6 CCTA 0.016 0.021 0.014 4.34 0.037
1–5 AACCT 0.01 0.015 0.009 4.49 0.034
Hypertension
1–8 GACCCACG 0.02 0.018 0.026 4.26 0.039
1–6 GACCCA 0.103 0.098 0.119 6.78 0.009
Type 2 diabetes mellitus
1–9 GACACACCC 0.18 0.192 0.175 4.05 0.044
Obesity
1–10 GACCCGCGCC 0.025 0.032 0.022 7.59 0.006**
GACCCGCGC 0.026 0.033 0.022 7.42 0.006**
2–10 ACCCGCGCC 0.026 0.031 0.022 6.55 0.011
3–10 CCCGCGCC 0.026 0.031 0.022 6.55 0.011
1–8 GACCCGCG 0.028 0.033 0.024 5.27 0.022
1–7 GACCCGC 0.028 0.033 0.024 6.14 0.013
4–10 CCGCGCC 0.026 0.031 0.022 5.97 0.015
3–9 CCCGCGC 0.027 0.033 0.023 6.88 0.009
2–8 ACCCGCG 0.028 0.033 0.025 4.53 0.033
3–8 CCCGCG 0.027 0.032 0.024 5.23 0.022
3–7 CCCGC 0.029 0.034 0.025 5.33 0.021
5–9 CGCGC 0.030 0.035 0.026 5.08 0.024
The table shows selected haplotypes associated with the disease. The most
frequent 10-mer haplotype (0.14) was employed as the baseline to determine
the relative effects of the other haplotypes. The studied SNPs are rs2740434
(also denoted as 1), rs17153743 (2), rs13264774 (3), rs56298569 (4), rs804280
(5), rs3729855 (6), rs3729856 (7), rs1062219 (8), rs11785481 (9) and rs3203358
(10) arranged sequentially by their chromosomal positions, whereby
blocks represent the range of variants constituting the respective haplotypes.
*p < 0.01; **p < 0.005 by χ2 test.
Table 2 Association of GATA4 gene variants with
metabolic disease risk traits
Block Haplotype Pooled Cases Control χ2 p value
Coronary artery disease
1–8 GACCCGTG 0.108 0.114 0.101 3.84 0.050
3–10 CCCGTGCC 0.110 0.116 0.102 4.17 0.041
2–9 ACCCGTGC 0.112 0.119 0.105 3.87 0.049
ACCCATGC 0.026 0.029 0.022 4.08 0.044
1–7 GACCCGT 0.109 0.116 0.102 3.93 0.048
CCCATGC 0.026 0.029 0.022 3.81 0.050
2–8 ACCCGTG 0.113 0.120 0.105 4.51 0.034
4–10 CCGTGCC 0.111 0.118 0.104 3.91 0.048
4–9 ACATCC 0.069 0.064 0.075 4.60 0.032
3–8 CCCGTG 0.114 0.121 0.106 4.63 0.031
2–7 ACCCGT 0.119 0.126 0.111 4.66 0.031
3–7 CCCGT 0.119 0.126 0.110 4.96 0.026
1–5 GACCC 0.239 0.250 0.228 5.48 0.019
4–8 CCGTG 0.116 0.122 0.108 4.21 0.040
1–4 GACC 0.244 0.254 0.232 5.69 0.017
4–7 CCGT 0.121 0.129 0.113 4.73 0.030
2–5 ACCC 0.403 0.416 0.387 7.17 0.007*
Myocardial infarction
1–10 AACACATCCC 0.04 0.038 0.049 6.01 0.014
1–9 AACACATCC 0.041 0.038 0.050 6.33 0.012
1–8 AACACATC 0.042 0.038 0.050 6.54 0.011**
2–9 ACCCACGC 0.029 0.033 0.023 6.58 0.010**
3–9 CCCACGC 0.029 0.032 0.023 5.97 0.015
2–8 ACCCACG 0.033 0.037 0.026 6.76 0.009**
6–10 GTCCC 0.014 0.016 0.011 3.84 0.050
4–8 CCACG 0.034 0.038 0.028 5.60 0.018
4–8 ATAC 0.013 0.010 0.018 7.98 0.005**
2–5 ACCC 0.403 0.410 0.387 4.07 0.044
The table shows selected haplotypes associated with disease. The most
frequent 10-mer haplotype (0.14) was employed as the baseline to determine
the relative effects of the other haplotypes. The studied SNPs are rs2740434
(also denoted as 1), rs17153743 (2), rs13264774 (3), rs56298569 (4), rs804280
(5), rs3729855 (6), rs3729856 (7), rs1062219 (8), rs11785481 (9) and rs3203358
(10) arranged sequentially by their chromosomal positions, and blocks represent
the range of variants constituting the respective haplotypes. *p < 0.01; **p < 0.005
by χ2 test.
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GATA4 Haplo Suppl data). A similar trend was observed
for the 8-mer GACCCGTG (χ2 = 3.84; p = 0.050) which
also culminated in the 4-mer GACC (χ2 = 5.69; p = 0.017)
showing the most significant association with the dis-
ease. Put together, these trends indicate that the
SNPs rs17153743 (2), rs13264774 (3), rs56298569 (4)
and rs804280 (5) constituted the primary core forthis association with CAD. Myocardial infarction was
equipotently linked to the 8-mer ACCCACGC (χ2 = 6.58;
p = 0.010) and its 7-mer derivative ACCCACG (χ2 = 6.76;
p = 0.009), thereby sharing with CAD, the same three
causative nucleotides of the four SNPs comprising the core
of the relationships. Notable relationships also included
the 10-mer AACACATCCC (χ2 = 6.01; p = 0.014) and the
4-mer ATAC (χ2 = 7.98; p = 0.005) showing the most
significant protective property against acquiring MI.
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ate dyslipidaemia-mediated onset of CAD, it was inter-
esting to investigate whether haplotyping might reveal
any link with lipidaemic disorders. Interestingly, hChol
(χ2 = 3.86; p = 0.050) and elevated hLDLC levels (χ2 = 4.94;
p = 0.026) shared the common 9-mer AACCCATGT, while
the 10-mer AACCCATGTC was associated with hLDLC
(χ2 = 4.83; p = 0.028), but only weakly so with hChol
(χ2 = 3.24; p = 0.072) (Table 4; Additional file 2, GATA4
Haplo Suppl data). Hypertriglyceridaemia (hTG) was linked
to the 5-mer ACCTA (χ2 = 4.65; p = 0.031), while low
high-density lipoprotein was associated with the CCCAC
(χ2 = 6.54; p = 0.011).
We then proceeded to investigate further potential re-
lationships of these haplotypes with other metabolic risk
traits, particularly hypertension, type 2 diabetes and
obesity. The results showed that a 10-mer GACCCGCGCC
(χ2 = 7.59; p = 0.006) was associated with obesity, while a
9-mer GACACACCC (χ2 = 4.05; p = 0.044) was implicatedTable 3 Association of GATA4 haplotypes with coronary arter
Variant Genotype/allele Controls Cases
Hypercholesterolaemia
rs804291CT TT 0.016 0.027
rs11785481CT CT + TT 0.196 0.220
rs3203358CG CG + GG 0.358 0.323
Hypertriglyceridaemia
rs3729855CT T 0.030 0.041
CT + TT 0.053 0.070
rs1062219CT TT 0.220 0.182
Elevated low-density lipoprotein-cholesterol
rs804291CT TT 0.018 0.033
rs11785481CT CT + TT 0.201 0.229
Low high-density lipoprotein-cholesterol
rs2740434CT CT + TT 0.084 0.069
Hypertension
rs3729855CT T 0.027 0.035
rs17153743AG AG + GG 0.017 0.031
rs13264774CT T 0.041 0.024
Type 2 diabetes mellitus
rs3729855CT T 0.040 0.028
rs13264774CT CT + TT 0.035 0.023
Obesity
rs17153743AG GG 0.138 0.070
rs11785481CT TT 0.029 0.022
rs2740434GA GA + AA 0.086 0.065
The table summarizes the univariate and multivariate analyses for the relationships
have been performed to adjust for age and sex and adjustment made for the confoin type 2 diabetes mellitus (Table 4). We also observed sev-
eral protective haplotypes for all disease traits, which were
primarily complementary to the core of the causative se-
quences (See also Additional file 2, GATA4 Haplo Suppl
data). However, we could not establish any significant
causative link with hypertension.
Discussion
In the present study, we first screened two families with
HFH in which the primary probands presented with se-
vere phenotypes of early onset CAD. We identified sev-
eral potential loci of which Chr 8 appealed as the most
attractive choice for detailed investigation on the genetic
basis for dyslipidaemia-related onset of the disease. This
locus harbours the GATA4 gene at Chr 8p23.1-22, which
we elected to study first as the most likely candidate.
Screening the complete coding and non-coding areas of
the gene revealed several mutations, among which we
selected 12 for the case-control study. The study hasy disease/myocardial infarction
Univariate analysis Multivariate analysis
p value Exp (B)(95% CI) Corrected
p value
Exp (B″)(95% CI)
0.023* 1.66(1.07–2.57) 0.037* 1.61(1.03–2.52)
0.065 1.16(0.99–1.34) 0.087 1.15(0.98–1.35)
0.020* 0.85(0.75–0.98) 0.026* 0.86(0.75–0.98)
0.023 1.35(1.01–1.78) 0.004** 1.49(1.14–1.94)
0.005** 1.34(1.09–1.64) 0.010* 1.47(1.10–1.96)
0.011* 0.79(0.67–0.98) 0.016* 0.80(0.67–0.99)
0.016* 1.90(1.13–3.21) 0.020* 1.87(1.10–3.15)
0.032* 1.18(1.01–1.37) 0.136 1.18(0.95–1.45)
0.013* 0.81(0.69–0.96) 0.744 0.93(0.62–1.41)
0.089 1.30(0.95–1.77) 0.013* 1.52(1.09–2.11)
0.022* 1.87(1.10–3.18) 0.005* 2.30(1.30–4.26)
0.008* 0.59(0.40–0.87) 0.085 0.68(0.44–1.05)
0.003* 0.70(0.55–0.89) 0.003* 0.68(0.53–0.88)
0.025* 0.66(0.045–0.95) 0.199 0.76(0.51–1.16)
0.031 0.73(0.55–0.98) 0.357 0.94(0.82–1.07)
0.033* 0.73(0.55–0.98) 0.903 0.84(0.73–0.95)
0.013* 0.73(0.50–0.94) 0.011* 0.72(0.56–0.93)
of the gene variants with various cardiovascular disease traits. Bonferroni tests
unders in the multivariate tests. *p < 0.05; **p < 0.005.
Muiya et al. Human Genomics 2013, 7:25 Page 6 of 11
http://www.humgenomics.com/content/7/1/25unequivocally identified two SNPs, the rs1062219 and
rs804280 as risk variants for CAD, both of which were
also linked to congenital heart disease in the present
study as well as other previous studies in different ethnic
populations [25,26,30]. Therefore, our study does not
only furnish strong support for an important role for
these SNPs in congenital heart disease, but also points
to a possible sharing of common disease pathways in-
volved in the etiologies of CAD and congenital heart dis-
ease at the GATA4 signaling level. Notably, by far, the
majority of GATA4 mutations studied to date seem to
point to their influencing its transcriptional activity, and
have been associated primarily with cardiac malforma-
tions, such as congenital heart disease. Thus, the differ-
ence in the nature of the congenital heart disease and
CAD etiologies renders it very intriguing why these two
disorders would share the GATA4, or any other signal-
ling pathway for that matter, as a common disease path-
way. A number of speculations have recently been
advanced on how changes in GATA4 gene may influence
disease pathways. One of these suggests an impediment
of the GATA4 transcription activity in congenital heart
disease as involving at least two of the variants, p.A348A
and p.S377G [26], which were also included in the
present study. Since GATA4 transcription activity is sub-
ject to regulation at the level of gene expression and
through post-translational modifications of protein, the
processes involved in these regulatory mechanisms are
therefore worthy considering as possible culprits in our
study. On the other hand, however, in our study, while
the former was implicated in MI, the latter was actually
protective against acquiring CAD. Accordingly, these ob-
servations seem to point to delineable differences between
CAD and congenital heart disease in their interactions
with the GATA4 variants. Besides, the ubiquity of GATA4
in the myocardium also raises fundamental questions
with respect to possible diversity in its cardiac-related
function(s) and its involvement in other cardiovascular
disease pathways, such as those leading to atherosclerosis.
Hence, the primary question raised in our study was
whether a link existed between the impact of GATA4 on
CAD manifestation and the presence of metabolic disor-
ders, as our linkage study in HFH seemed to suggest.
To begin with, our results pointed to an association of
the rs804291 and rs11785481 with both hChol and hLDLC,
which appeared to follow primarily an autosomal recessive
mode of inheritance. A closer analysis of the data also indi-
cated that while the rs11785481 was not directly related to
CAD per se, the probability of an individual acquiring CAD
increased greatly in hypercholesterolaemic individuals. We
also noted that two other SNPs that were not directly asso-
ciated with hChol became so in the presence of MI, simi-
larly indicative of a possible interaction of the dyslipidaemic
disease traits with changes in GATA4 as a possible link toCAD/MI manifestation in these individuals. Moreover, the
analyses for the other metabolic risk factors revealed the as-
sociation for two variants with hypertension, further linking
risk traits for metabolic syndrome to GATA4 polymorph-
ism. Altogether, these observations furnish support for the
notion of a contribution of some interactions of metabolic
risk traits with GATA4 to the disease pathways leading
to atherosclerosis, an assertion which requires further
investigation.
The various ways in which the GATA4 variants relate to
alterations in lipid levels and CAD/MI in this study lead to
important questions regarding the possible mechanisms or
pathways linking them with one another. Based on our re-
sults, it appears that such mechanisms may involve events
associated with the harbouring of lHDLC, for example, be-
ing linked to pathways directly influencing circulating lipid
levels and possibly leading to acquiring CAD in dyslipidae-
mic individuals, as indicated by the inverse relationship of
some of these traits with the different GATA4 variants. Ac-
cordingly, the processes appear to be separable from those
leading to cardiac malformations. Hence, the novel finding
implicating the GATA4 in dyslipidaemia seems to point to
yet undefined entities, possibly involving the regulation of
the GATA4 functional state, as playing an important role in
the disease process. In this regard, perhaps the most reveal-
ing observation of the present study is the linking of non-
coding variants of the gene to disease. Of particular interest
was the finding of causative haplotypes for CAD/MI as well
as the metabolic risk traits encompassing variants in the 3′-
UTR of the gene. Thereby, isolating the two coding SNPs
from those residing in the 3′-UTR did not alter the signifi-
cance level for the latter, possibly pointing to the changes at
this chromosomal locus rather than the individual variants
as the underlying genetic basis for these manifestations.
Notably, the significance levels for the haplotype associa-
tions were higher than those of individual constituent
variants, pointing to the importance of these genomic se-
quences in revealing the impact of a gene on disease that
would otherwise remain uncovered through associations
with changes at individual loci. Implications are that these
events may be due to changes other than those directly per-
taining to a functional motif of the GATA4 protein. Fur-
thermore, the close proximity of these variants may also
suggest the presence of sequences encoding some other yet
unidentified entities as the potential culprits, especially con-
sidering the fact that several 3-mer haplotypes at this locus
were shared by some of the traits. Thus, it is plausible to
postulate that alteration at this genomic locus, and not ne-
cessarily in the GATA4 gene function per se, may offer an
explanation for the observed link to alterations in the meta-
bolic risk traits and CAD manifestation.
A number of speculations have been raised with regard
to the possible ways in which changes in the 3′-UTR of
the GATA4 gene may influence disease pathways. For
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cently been described in this region that were predicted
to affect RNA folding as cause for congenital heart disease
[25]. This is in line with the notion that the mechanisms
by which GATA4 contributes to hChol metabolism may
be related to the regulation of the gene itself or its mRNA
maturation rather than the transcriptional activity of its
protein product. These mechanisms are likely to be the re-
sult of complex interactions with yet unidentified co-
factors, as has been suggested recently by some studies
[6]. While the study has produced interesting data that
may contribute to our knowledge of GATA4 interaction
with cardiovascular disease, there are some limitations in
the extent of its applicability. Thus, one of the main limi-
tations is that no such potential mechanisms were tested
to verify the notion that the 3′-UTR of the GATA4 gene
plays an important role in the discussed cardiovascular
disease pathways. Furthermore, like other association
studies on complex diseases, the potential impact of the
present findings may be limited to ethnic Arab popula-
tions due to inter-ethnic variations in prevalent epigenetic
and environmental factors. Besides, it is not likely that our
present findings per se can be exploited as predictive
markers for the dyslipidaemic disorders.
Conclusion
In summary, our study identified the GATA4 transcription
factor as an independent risk factor for congenital heart
disease and CAD/MI and a metabolic risk trait for cardio-
vascular diseases. Thus, apart from the demonstrated
association of GATA4 polymorphism with dyslipidaemia,
our results also point to interrelationships of the two
disease components with CAD/MI, which may explain
partly how these diseases lead to atherosclerosis. The find-
ing of several causative haplotypes for MI/CAD embracing
the 3′UTR of the GATA4 gene points to important roles
for this chromosomal locus in the etiology of CAD/MI
and the possible involvement of yet undefined entitiesFigure 3 Pedigrees of two families with heterozygous hyperlipidaemi
at the age of 14 years, as well as D6 and D7 in Family Two presented withrelated to GATA4 transcription activity or gene regulatory




The present study was performed in three stages involv-
ing three independent groups of Saudi individuals. The
first group comprised two families of a total of 22 mem-
bers in which HFH was prevalent (Figure 3). The index
case of the first family was the third (S3) of seven sons
and two daughters born to unrelated parents, who
underwent triple coronary artery bypass surgery at the
age of 14 years. On admission, this propositus had re-
ported with a chest wound and xanthomas, as well as
clinical features of bilateral carotid artery disease and a
very severe form of familial hyperlipidaemia (FH). He
presented with very high cholesterol (Chol) level of
10.1 mmol/L (desirable <5.2 mmol/l) and LDL-Chol
level of 7.9 mmol/L (optimal <2.59 mmol/l). Further-
more, he harboured low HDL-Chol levels (0.51 mmol/l;
normal 1.04–1.55). The father displayed the characteristics
of borderline HFH (Chol 6.1 mmol/L, LDL 4.0 mmol/L),
while the mother, two other sons (S4 and S6) and a daugh-
ter (D2) had clinical phenotypes of the disease (combination
of high Chol (≥6.2 mmol/L) and high LDL-Chol
(≥4.12 mmol/L)). Two other sons with otherwise normal
Chol and LDL-Chol levels also displayed low HDL-Chol
levels (<1.04 mmol/L), while none of the family members
had isolated elevated LDL-Chol levels. In the second family,
two index cases, two daughters of a family of seven daugh-
ters and two sons concurrently presented with early onset
CAD at the age of 17 and 15 years. The two candidates had
identical exceedingly high Chol levels of 22.5 mmol/l and
LDL-Chol levels of 19.6 (D6) and 18.0 mmol/l (D7), in
addition to harbouring low HDL levels of 0.93 and
0.65 mmol/l, respectively. The father (8.6 mmol/l), mother
(7.7 mmol/l) and a third daughter (D3; 7.6 mmol/l) werea. Proband S3 in Family One underwent triple coronary artery bypass
early onset coronary artery disease at the age of 17 and 15 years.
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familial hyperlipidaemia (FH) were adapted from our Insti-
tutional Guidelines, employing the reference values ap-
proved by the USA National Cholesterol Education
Program (NCEP). Following the identification of Chr 8p23
region, which harbours the GATA4 gene (8p23.1-22), as a
potential culprit for the disease through linkage study of
the above two families, we elected to sequence the gene in
the two families and a group of 250 healthy blood donors
visiting our Blood Bank Clinic to identify potentially in-
formative SNPs of interest for the case-control association
study.
The case-control study was performed in a total of
4,274 Saudi individuals consisting of 2,274 CAD patients
(1,736 males and 538 females, mean age 60.8 ± 0.4 years)
with angiographically determined narrowing of the cor-
onary vessels by at least 50% and 2,004 angiographed
controls (1,074 male and 930 female, mean age 50.2 ±
0.5 years) (Table 5). These controls (CON) were individ-
uals undergoing surgery for valvular disease or reporting
for follow-up on various other cardiac procedures, but
were established to have no significant narrowing of the cor-
onary vessels. Among the study population, 1,590 patients
were hypercholesterolaemic (hChol) patients (1,051 male
and 539 female, mean age 58.2 ± 0.2 years) undergoing anti-Table 4 Association of GATA4 haplotypes with metabolic dise
Controls
All Male Fe
Gender 2,004 1,074 (53.6) 930
Age 50.2 ± 0.5 50.81 ± 0.5 49.6
BMI 29.4 ±0.2 28.01 ± 0.2 30.6
MI 1,388 684 (0.49) 704
T2DM 1,900 1,220 (0.64) 680
HTN 966 650(0.67) 314
lHDLC 2,209 1,262 (0.57) 947
hLDL 3,404 2,267 (0.67) 1,13
hTG 2,896 1,859 (0.64) 1,03
hChol 2,487 1,639 (0.66) 848
CHD 4,128 2,741 (0.66) 1,38
FH 3,421 2,255 (0.66) 1,16
OBS 2,362 1,729 (0.73) 633




More than two 0 0
The numbers in brackets give the percentages of the total (all) values of the group.
CAD; MI, myocardial infarction; lHDLC, low high-density lipoprotein-cholesterol leve
T2DM, type 2 diabetes mellitus; VD, number of diseased vessels.hyperlipidaemic therapy and/or known to have high levels
of total cholesterol (Chol >6.20 mmol/L), 1,776 patients har-
boured lHDLC levels (<1.04 mmol/L), 1,088 had high trigly-
ceride (hTG) levels (>2.25 mmol/L), and 575 exhibited high
low-density lipoprotein levels. These were denoted as dysli-
pidaemia study patients. Another subset of interest com-
prised 2,378 individuals having type 2 diabetes mellitus
(T2DM; formerly known as non-insulin-dependent diabetes
mellitus or adult-onset diabetes). The National Diabetes
Data Group of the USA and the second World Health
Organization Expert Committee on Diabetes Mellitus
(1998) [31] define type 2 diabetes mellitus as a meta-
bolic disorder that is characterized by high blood glu-
cose (generally defined as fasting glucose level >126 mg/dL)
in the context of insulin resistance and relative insulin defi-
ciency. Furthermore, 3,312 individuals had primary (essen-
tial) hypertension (HTN) (Table 5), defined as ≥140 mm Hg
systolic blood pressure or ≥90 mm Hg diastolic pressure
based on The Sixth Report of the Joint National Commit-
tee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC VI) criteria [32]. Accordingly,
essential, primary, or idiopathic hypertension is defined
as high blood pressure in which secondary causes such as
renovascular disease, renal failure, pheochromocytoma, al-
dosteronism, or other causes of secondary hypertension orase risk traits
Cases
male All Male Female
(46.4) 2,274 1,736 (76.3) 538 (23.7)
6 ± 0.5 60.8 ±0.4 59.7 ± 0.3 61.8 ± 0.5
9 ± 0.2 29.7 ± 0.2 28.3 ± 0.1 31.1 ± 0.3
(0.51) 2,890 2,126 (0.74) 764 (0.26)
(0.36) 2,378 1,590 (0.67) 788 (0.33)
(0.33) 3,312 2,158 (0.65) 1,154 (0.35)
(0.43) 1,776 1,371 (0.77) 405 (0.23)
7 (0.33) 575 364 (0.63) 211 (0.37)
7 (0.36) 1,088 773 (0.71) 315 (0.29)
(0.34) 1,590 1,051 (0.66) 539 (0.34)
7 (0.34) 150 69 (0.46) 81 (0.54)
6 (0.34) 857 555 (0.65) 302 (0.35)
(0.27) 1,631 895 (0.55) 736 (0.45)
2 (0.53) 1,619 1,547 (0.96) 72 (0.04)
0 847 614 (0.72) 233 (0.28)
0 456 355 (0.78) 101 (0.22)
0 971 767 (0.79) 204 (0.21)
BMI, body mass index; CHD, congenital heart disease; FH, family history of
l; hTG, hypertriglyceridaemia; hChol, hypercholesterolaemia; HTN, hypertension;
Table 5 Patient Demographics and clinical data
Variant Genotype/allele Controls Cases Univariate analysis Multivariate analysis




rs3729855CT T 0.037 0.030 0.047* 0.78(0.62–1.00) 0.315 0.87(0.67–1.14)
rs3203358CG G 0.206 0.191 0.074 0.90(0.82–1.00) 0.042* 0.88(0.78–0.99)
rs1062219CT CT + TT 0.663 0.694 0.034* 1.15 (1.01–1.31) 0.091 1.13(0.98–1.31)
rs17153743AG AG + GG 0.033 0.022 0.036* 0.67(0.47–0.98) 0.032* 0.67(0.43–0.96)
rs804280AC C 0.420 0.446 0.018* 1.11(1.02–1.21) 0.009* 1.14(1.03–1.27)
AC + CC 0.647 0.688 0.005** 1.20(1.06–1.36) 0.012* 1.20(1.03–1.39)
Myocardial infarction
rs3729855CT T 0.040 0.030 0.020* 0.75(0.59–0.96) 0.323 0.86(0.86–1.56)
rs3729856AG GG 0.031 0.041 0.024* 1.34(1.04–1.72) 0.146 1.42(0.88–2.33)
rs13264774CT CT + TT 0.269 0.247 0.029* 0.89(0.80–0.99) 0.103 0.84(0.69–1.04)
rs804280AC AC + CC 0.645 0.681 0.020* 1.17(1.07–1.29) 0.511 1.07(0.88–1.28)
Congenital heart disease
rs3729856AG G 0.145 0.215 0.012* 1.61(1.11–2.30) 0.081 1.51(0.95–2.40)
AG + GG 0.280 0.362 0.018* 1.45(1.07–1.99) 0.108 1.57(0.90–2.73)
rs12825CG CG + GG 0.777 0.854 0.010* 1.68(1.13–2.50) 0.108 1.71(0.89–3.29)
rs11785481CT T 0.115 0.154 0.037* 1.41(1.02–1.94) 0.030* 1.78(1.06–3.00)
CT + TT 0.190 0.275 0.053* 1.61(1.15–2.27) 0.183 1.50(0.83–2.75)
rs2740434CT CT + TT 0.073 0.123 0.020* 1.78(1.09–2.89) 0.403 0.70(0.30–1.63)
rs13264774CT CT + TT 0.267 0.205 0.057 0.71(0.049–1.01) 0.238 0.69(0.38–1.27)
The table summarizes the univariate and multivariate analyses for the relationships of the gene variants with coronary artery disease, myocardial infarction and
congenital heart disease in the studied 4,278 individuals. Bonferroni tests have been performed to adjust for age and sex, and adjustment made for the
confounders in the multivariate tests.*p < 0.05; **p < 0.005.
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group comprised 1,631 obese candidates with body-mass
index (BMI) of ≥30.0 kg/m2, and classified as the obesity
subset. Among these subsets of patients, some patients
harboured a combination of two or possibly three of the
cardiovascular risk traits. All individuals with major cardiac
rhythm disturbances, incapacitating or life-threatening
illness, major psychiatric illness or substance abuse, history
of cerebral vascular disease, neurological disorders, and ad-
ministration of psychotropic medication or any other disor-
ders likely to interfere with variables under investigation
were excluded from the study. This study was performed in
accordance with the regulations laid down by the King
Faisal Specialist Hospital and Research Centre Ethics
Committee in compliance with the Helsinki Declaration
[33] and all participants signed an informed consent.
Five millilitres of peripheral blood was sampled in
EDTA tubes after obtaining written consent, and gen-
omic DNA extracted from leukocytes by the standard
salt methods using PUREGENE DNA isolation kit
(Qiagen, Germantown, MD, USA).Linkage analysis and gene sequencing
Whole genome-wide scanning of two families with hetero-
zygous familial hypercholesterolaemia was performed
using the Affymetrix Gene Chip 250 Sty1 mapping array
(Affymetrix, Inc., Santa Clara, CA, USA), and multipoint
parametric linkage analysis for estimating the LOD scores
performed using the GeneHunter Easy Linkage analysis
software 4.0 (Affymetrix, Inc., Santa Clara, CA, USA) as
described previously [34]. A recessive model of inherit-
ance was used with a population-disease allele frequency
of 0.0001, based on the Asian SNP allele frequencies, and
the Copy Number Analyzer for GeneChip® (CNAG) Ver.
3.0 (Affymetrix, Inc., Santa Clara, CA, USA) software was
employed in order to search for shared chromosomal re-
gions of homozygosity. Following the identification of Chr
8 as a potential risk locus, screening for GATA4 mutations
of interest was accomplished by sequencing on the
MegaBACE DNA analysis system (Amersham Biosciences,
Sunnyvale, CA, USA). Briefly, the DNA was subjected to
PCR amplification by standard methods, following which
the PCR products were sequenced and the data analyzed
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Madison, WI, USA) as described previously [35].Association studies
Following the identification of possible informative vari-
ants based on the screening of our general population,
genotyping was accomplished using Taqman chemistry on
the Applied Biosystems Prism 7900HT Sequence Detection
System (ABI Inc., Foster City, CA, USA). Primers and
the TaqMan probes were procured from Applied Biosystems
(ABI, Warrington, UK), and assays run by standard methods
(Eurogentec, Seraing, Belgium) on the ABI2720 thermocycler
(ABI Inc., Foster City, CA, USA). The plates were then
scanned for FRET signal and data analyzed using Applied
Biosystems SDS 2.4 software.Statistical analysis
Comparison of genotypes and alleles between different
groups for continuous dependent variables was achieved
by Analysis of Variance (ANOVA) or Student's t test as
appropriate. Categorical variables were analyzed by Chi-
square test, and logistic regression analysis was used to
compute odds ratios and their 95% confidence intervals.
The Bonferroni test was employed to correct for the po-
tential impact of the classical confounders, such as age,
sex, smoking and disease history for all studied disease
traits. Initially, univariate analysis was performed for in-
dividual SNPs to test for their possible association with
the different traits. For the SNPs, that showed a signifi-
cant value at p < 0.05, we then performed two tests,
multivariate and multinomial regression analyses to test
for possible confounding effects of the different disease
traits in the model. The Haplo.stats package [36] in the
R Statistical Computing software [37] was used to per-
form haplotype-based association analysis. Odd ratios
for haplotypes were calculated using the baseline 10-mer
haplotype GACACACCCG (global score statistics = 14.4)
as reference, and the Haplotype Score statistic for the as-
sociation of a haplotype with the binary trait was calcu-
lated as in [38] and [39]. Significance of association was
determined between haplotypes and the case-control
status - a binomial trait denoting whether or not a
patient had the disease. All other statistical analyses
were performed using the SPSS software Version 20
(SPSS Inc., Chicago, IL, USA), and data are expressed as
mean ± SEM. Associations with a two-tailed p value < 0.05
was considered statistically significant.Additional files
Additional file 1: GATA4 Suppl data: analysis for GATA4 interaction
with age, sex and other confounders for the analyses of the
different disease traits.Additional file 2: GATA4 Haplo Suppl data: GATA4 haplotyping for
the cardiovascular disease traits.
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